New trials, publications, preprints and grants on this target, month by month.
Publication
Quantitative systems pharmacology modeling identifies synthetic lethality opportunities with DNA damage response inhibitors in ATM-deficient chronic lymphocytic leukemia - a computational simulation study.
3 Nov 2026· Journal of pharmacokinetics and pharmacodynamics· PUBMED
Publication
Methylmalonic Acid Induces Oxaliplatin Resistance Through Promoting DNA Damage Repair via the ATM/ATR Pathway in Gastric Cancer.
15 Oct 2026· FASEB journal : official publication of the Federation of American Societies for Experimental Biology· PUBMED
Publication
Retraction Note: In silico and in vitro assessment of TP53, ATM, RAD51, and BAX genes in gastric cancer and their contribution to radiotherapy resistance.
10 Oct 2026· Hereditas· PUBMED
Preprint
Combined HDAC and ATM inhibition with radiation in preclinical glioblastoma models.
7 Oct 2026· bioRxiv : the preprint server for biology· PUBMED
Publication
ATM mutations in myelodysplastic neoplasms, acute myeloid leukemia, and myeloproliferative neoplasms: a systematic review.
25 Sept 2026· Medical oncology (Northwood, London, England)· PUBMED
Publication
A rare ATM variant in a Colombian family with chorea-ataxia syndrome: implications for an early diagnosis.
24 Sept 2026· Neurogenetics· PUBMED
Publication
Fermented wheat germ extract modulates organic selenium availability to regulate programmed cell death and metabolic reprogramming through the ATM/ATR/p53 pathway.
23 Sept 2026· Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS)· PUBMED
Publication
ATM inhibition attenuates ferroptosis-associated injury and reduces infarct volume in experimental stroke.
22 Sept 2026· Ferroptosis and oxidative stress· PUBMED
Publication
The ATM inhibitor KU55933 inhibits TGF-β1-mediated epithelial to mesenchymal transition in colorectal cancer cells.
21 Sept 2026· Frontiers in oncology· PUBMED
Publication
Inhibition of ATM, ATR and DNA-PK radiosensitises 3D uveal melanoma models to X-rays and proton beam therapy.
14 Aug 2026· Frontiers in oncology· PUBMED
Publication
Nuclear SOD1 links ATM-CHK2 signaling to ADH5/GSNOR transcription in SHSY-5Y SOD1G93A cellular models of ALS.
12 Aug 2026· Nitric oxide : biology and chemistry· PUBMED
Publication
Epigenetic LOCK chromatin links H3K9 modifications to ATM-γH2AX signaling in HIV-Tat and opioid neuroinflammation.
5 Aug 2026· Cell death & disease· PUBMED
Publication
MPT0E028, a pan-HDAC inhibitor, ameliorates bleomycin-induced pulmonary fibrosis by promoting AT2-to-AT1 differentiation through the ATM/AMPK/FoxO1 pathway.
21 Jul 2026· Journal of biomedical science· PUBMED
Publication
ATM Deficiency Induces TGFβ-Mediated Stromal Programming in Pancreatic Cancer.
15 Jul 2026· Cancer research· PUBMED
Publication
Pemetrexed potentiates γδ T cell-based immunotherapy in NSCLC through ATM-STING-NF-κB-mediated induction of NKG2D ligands.
14 Jul 2026· International immunopharmacology· PUBMED
Publication
Cancer-related microangiopathic hemolytic anemia (CR-MAHA) in a metastatic breast cancer patient with a germ-line ATM single nucleotide variant and an ESR1 fusion variant: insights from a case report on early diagnosis and improved outcomes.
7 Jul 2026· Frontiers in oncology· PUBMED
Publication
Ceralasertib Monotherapy in Patients with ATM-Altered Advanced Solid Tumors or Metastatic Castration-Resistant Prostate Cancer: Data from the Phase IIa PLANETTE Study.
1 Jul 2026· Cancer research communications· PUBMED
Trial
Human ADME Study of [14C]-AZD1390
30 Jun 2026· PHASE1 · NOT_YET_RECRUITING· CTGOV
Publication
ATM c.7374_7375insAlu is a French-Canadian founder pathogenic variant associated with predisposition to pancreatic and breast cancer.
25 Jun 2026· Journal of medical genetics· PUBMED
Publication
Suppression of ATM kinase signaling accelerates cellular senescence.
11 Jun 2026· Stem cell reports· PUBMED
Publication
Impact of ataxia-telangiectasia mutated (ATM) loss on radiobiological and immune response to radium-223 in prostate cancer in vitro models.
30 May 2026· Clinical and translational radiation oncology· PUBMED
Publication
Reply to the letter of editor addressed by Thulamy Raman D. Et al., about our article entitled "Radiosensitivity and delayed radiation-induced Nucleo-shuttling of the ATM protein in fibroblasts from Duchenne muscular dystrophy expressing residual dystrophin".
23 May 2026· Journal of the neurological sciences· PUBMED
Publication
Comment on "Radiosensitivity and delayed radiation-induced nucleo-shuttling of the ATM protein in fibroblasts from Duchenne muscular dystrophy expressing residual dystrophin".
22 May 2026· Journal of the neurological sciences· PUBMED
Publication
ATR inhibition in combination with hypofractionated radiotherapy is superior to ATM inhibition with regard to ex vivo CD8 + T cell activation particularly for HPV-negative head and neck cancer cells.
19 May 2026· Oral oncology· PUBMED
Preprint
Ablation of glypican-3 enhances radiosensitivity in liver cancer by prolonging G2/M arrest and activating the ATM/CHK2 pathway.
14 May 2026· bioRxiv : the preprint server for biology· PUBMED
Publication
The Mechanism of Mg2+-Mediated Inhibition of Cervical Cancer by Inducing a Senescence-like State via the ATM/CHK2/p21 Signaling Pathway.
14 May 2026· International journal of molecular sciences· PUBMED
Publication
Comment on "Radiosensitivity and delayed radiation-induced nucleo-shuttling of the ATM protein in fibroblasts from Duchenne muscular dystrophy expressing residual dystrophin".
7 May 2026· Journal of the neurological sciences· PUBMED
Publication
PARG inhibition in ATM-deficient prostate cancer: from mechanistic discovery to therapeutic potential.
6 May 2026· Journal of translational medicine· PUBMED
Publication
Reply to the Letter of Editor addressed by D.M. Sati et al., about our article entitled "Radiosensitivity and Delayed Radiation-Induced Nucleo-shuttling of the ATM Protein in Fibroblasts from Duchenne Muscular Dystrophy Expressing Residual Dystrophin".
5 May 2026· Journal of the neurological sciences· PUBMED
Publication
A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2.
1 May 2026· Clinical cancer research : an official journal of the American Association for Cancer Research· PUBMED